@inproceedings{inproceedings, title  = {{ASCT2A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial}},

 url = {{}},

 year = {{2015}},

 month = {{12}},

 author = {{Cook G and Williams C and Cairns DA and Hockaday A and Cavenagh J and Snowden JA and Parrish C and Yong KL and Cavet J and Hunter H and Bird J et al}},

 volume = {{126}},

 journal = {{BLOOD}},

 issue = {{23}},

 note = {{Accessed on 2024/12/28}}}